By 2025-End, Global Immuno-Oncology Market Will Reach a Valuation of US$ 27,846.3 Mn
Owing to higher efficiency as compared to conventional therapies such as radiation, chemo and surgery, doctors around the globe are increasingly prescribing immunotherapy to cancer patients. Immuno-oncology therapies have low toxicity, making it easier for the patients to undergo such treatment procedures. Increasing clinical approval of immunotherapy drugs continues to support speedy adoption of immuno-oncology treatments while higher investments to further improve immunotherapies is anticipated to create greater market opportunities for drug makers. Persistence Market Research (PMR) is its latest report projects that the global market for immune-oncology is set to witness a CAGR of 16.5% between 2016 and 2025, to reach a valuation of US$ 27,846.3 Mn by the end of the forecast period. Collaborative efforts and initiatives to identify therapies for difficult-to-treat illnesses is a key factor driving the overall immune-oncology market. However, high drug pricing, development costs and limited technical expertise are some of the challenges likely to dampen the surging spirit of the market over 2025. Download Sample Report @ http://www.persistencemarketresearch.com/samples/11329 Currently, immune checkpoint inhibitor therapy is widely used for treating several carcinogenic disorders. Immune checkpoint inhibitor drugs help the body fight against certain proteins that are normally used by various tumors to suppress immune responses. Sales revenue from immune checkpoint inhibitors drugs is anticipated to reach US$ 7,321.7 Mn by 2017-end. Of late, a number immune checkpoint inhibitor drugs have been approved by the US FDA including Yervoy (anti-